WO2004026814A2 - Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors - Google Patents
Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors Download PDFInfo
- Publication number
- WO2004026814A2 WO2004026814A2 PCT/US2003/028661 US0328661W WO2004026814A2 WO 2004026814 A2 WO2004026814 A2 WO 2004026814A2 US 0328661 W US0328661 W US 0328661W WO 2004026814 A2 WO2004026814 A2 WO 2004026814A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- formula
- carbon atoms
- chain alkyl
- straight chain
- Prior art date
Links
- 0 C*(C(C(*)(*)c1ccccc1)C(*)=O)C(O*)=O Chemical compound C*(C(C(*)(*)c1ccccc1)C(*)=O)C(O*)=O 0.000 description 13
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
- C07C45/58—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- This invention relates to a novel process for the preparation of racemic and asymmetric intermediates useful for the preparation of tubulin inhibitors which are useful in the treatment of cancer.
- Hemiasterlin analogs 1 with substituents as reported are synthesized by coupling carboxylic acid 2, with intermediate amine 3.
- the present invention provides a process for the preparation of a compound of Formula I:
- R., and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- R 5 is straight chain alkyl of 1 to 4 carbon atoms
- step b) reacting the aldehyde (step a) with alkali metal cyanide in the presence of an alkylamine of the formula R 5 NH 2 to obtain a nitrile of the formula:
- step b) hydrolyzing the nitrile (step b) with an alkali metal hydroxide to give an amide of the formula:
- step d) reacting the amide (step c) with an organic carbonate of the formula 0[C0 2 R 4 ] 2 to give optionally isolated blocked amine of the formula:
- step d reacting optionally isolated blocked amine (step d) with an organic carbonate of the formula O[CO 2 R ] wherein each R 4 is taken independently in the presence of dimethylaminopyridine(DMAP) to obtain a triblocked amide of the formula:
- step e hydrolyzing triblocked amide (step e) with an alkali metal base to give racemic blocked amine of the formula:
- step f reacting racemic blocked amine (step f) with a resolving base (NH 2 -resolving base) to obtain a resolved blocked amine salt of the formula:
- step g treating the resolved blocked amine salt (step g) with an aqueous alkali metal hydroxide and acidifying with acid to give a compound Formula I:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- R 5 is straight chain alkyl of 1 to 4 carbon atoms
- step b) reacting the aldehyde (step a) with alkali metal cyanide in the presence of an alkyl amine of the formula R 5 NH 2 to obtain nitrile of the formula:
- step b) hydrolyzing the nitrile (step b) with an alkali metal hydroxide to give an amide of the formula:
- step d) reacting the amide (step c) with an organic carbonate, of the formula O[C0 2 R 4 ] 2 in the presence of dimethylaminopyridine (DMAP) to obtain a triblocked amide of the formula:
- step d hydrolyzing triblocked amide (step d) with an alkali metal hydroxide to give racemic blocked amine of the formula:
- step f reacting racemic blocked amine (step e) with a resolving base (NH 2 -resolving base) to obtain a resolved blocked amine salt of the formula:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- R 5 is straight chain alkyl of 1 to 4 carbon atoms
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- R 5 is straight chain alkyl of 1 to 4 carbon atoms
- step b hydrolyzing the nitrile (step a) in the presence of an alkali metal hydroxide to obtain amide of the formula:
- step b) reacting the amide (step b) with an organic carbonate of the formula O[C0 2 R 4 ] 2 to obtain blocked amine of the formula:
- step c hydrolyzing triblocked amide (step c) with an alkali metal hydroxide and acidifying with acid to obtain a compound of Formula I:
- a further embodiment of the present invention provides a process for the preparation of a compound of Formula I:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- R 5 is straight chain alkyl of 1 to 4 carbon atoms
- step b hydrolyzing the nitrile (step a) in the presence of an alkali metal hydroxide to obtain an amide of the formula:
- step b) reacting the amide (step b) with an organic carbonate of the formula 0[CO 2 R ] 2 in the presence of dimethylaminopyridine (DMAP) to give triblocked amide of the formula:
- step c hydrolyzing triblocked amide (step c) with an alkali metal hydroxide and acidifying with acid to obtain a compound of Formula I:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- A is selected from the group
- Ri and R2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R3 is straight chain alkyl of 1 to 4 carbon atoms
- R5 is straight chain alkyl of 1 to 4 carbon atoms
- R4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- step b) hydrolyzing the ester of step a) with an alkali metal hydroxide and acidifying with acid affords a carboxylic acid of the formula:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 5 is straight chain alkyl of 1 to 3 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- step b) hydrolyzing the ester of step a) with an alkali metal hydroxide and acidifying with acid to obtain a carboxylic acid of the formula:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 5 is straight chain alkyl of 1 to 3 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- step b) hydrolyzing the ester of step a) with an alkali metal hydroxide and acidifying with acid to obtain a carboxylic acid of the formula:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms
- R5 is straight chain alkyl of 1 to 4 carbon atoms
- step b reducing a nitrile of step a with a reducing agent to give an aldehyde of the formula:
- An additional embodiment of the present invention provides a process for the preparation of a compound of the formula: wherein:
- Ri and R 2 are independently selected from H, straight chain alkyl of 1 to 4 carbon atoms, halogen and alkoxy of 1 to 4 carbon atoms;
- R 3 is straight chain alkyl of 1 to 4 carbon atoms
- R 4 is straight chain alkyl of 1 to 4 carbon atoms and branched chain alkyl of 3 to 4 carbon atoms;
- R 5 is straight chain alkyl of 1 to 4 carbon atoms
- the present invention provides the following compounds:
- N-(tert-butoxycarbonyl)-N, ⁇ , ⁇ -trimethyl-L-phenylalaninamide N,N,N-tris(tert-butoxycarbonyl)-N, ⁇ , ⁇ -trimethyl-L-phenylalaninamide, salt of N-(tert-butoxycarbonyl)-N, ⁇ , ⁇ -trimethyl-L-phenylalanine with (S)-(-)- ⁇ - methylbenzylamine (SAMBA) and salt of N-(tert-butoxycarbonyl)-N, ⁇ , ⁇ -trimethyl-D-phenylalanine with (R)-(+)- - methylbenzylamine (RAMBA).
- Halogen as used herein means fluoro, chloro, bromo and iodo.
- Alkyl as used herein means a straight chain having from 1 to 4 carbon atoms.
- Exemplary alkyl groups include methyl, ethyl, propyl, and butyl.
- Straight chain alkyl as used herein means a straight chain having from 1 to 4 carbon atoms.
- exemplary alkyl groups include methyl, ethyl, propyl, and butyl.
- Branched chain alkyl as used herein means a branched chain having 3 or 4 carbon atoms.
- Exemplary branched alkyl groups include isopropyl and tertiary butyl.
- Alkoxy as used herein means an alkyl-O- group in which the alkyl group is as previously described.
- Exemplary alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, and n-butoxy.
- a strong base as used herein means a tert-butoxyalkali metal base.
- Additional strong bases include sodium hydride, potassium hydride, sodium hydroxide, and lithium diisopropylamide.
- Preferred strong bases include potassium fert-butoxide ('BuOK), sodium fe/f-butoxide ('BuONa), or lithium fe/f-butoxide BuOLi), most preferably potassium terf-butoxide ( f BuOK).
- Alkali metal cyanide as used herein means an alkali metal cyanide salt.
- Alkali metal hydroxide preferably, means sodium hydroxide, potassium hydroxide and lithium hydroxide, most preferably lithium hydroxide.
- Reducing agent as used herein means an agent which adds hydride and includes tin chloride/hydrochloric acid, lithium aluminum hydride and diisobutylaluminum hydride (DIBAL-H).
- Oxidizing agent as used herein means an agent which has an 0-0 bonding such as hydrogen peroxide.
- Organic carbonate as used herein means a compound of the formula 0[C0 2 R 4 ] 2 where R 4 is alkyl as previously defined. Preferred is t-butyl dicarbonate when t means tert.
- Organic base as used herein means an alkylamine base which includes triethylamine, N,N-diethylmethylamine, N,N-diethylaniline, N,N- diethylethylenediamine, or N,N-diisopropylethylamine.
- Further organic bases include dimethylaminopyridine(DMAP) with diisopropylethylamine (DIEA), N- methylmorpholine, N-methylpyrrolidine, 2,6-di-tertbutyl-4-methylpyridine or pyridine.
- a resolving base as used herein means a chiral amine (R or S) capable of forming a pair of salts (R and S) with a racemic carboxylic acid.
- the pair of salts are capable of being separated one from the other by crystallization or high pressure liquid chromatography.
- Exemplary resolving bases include (S)-(-)- ⁇ - methylbenzylamine, (S)-(-)- ⁇ -methyl-4-nitro-benzylamine, (1 R,2S)-(-)-norephedrin, (1S,2R)-(+)-norephedrin and (R)-(+)- ⁇ -methylbenzylamine.
- Preferred strong bases include potassium ferf-butoxide ('BuOK), sodium ferf-butoxide ('BuONa), or lithium ferf-butoxide ('BuOLi), most preferably potassium ferf-butoxide ('BuOK), and an alkylating agent R 3 LG where R 3 is hereinbefore defined and LG is a leaving group which includes but not limited to chloro, bromo, p-toluenesulfonyl and methanesulfonyl.
- Preferred alkylating agents include methyl iodide or methyl bromide, most preferably iodomethane (methyl iodide) (CH 3 I) or alternatively methyl bromide in the presence of sodium iodide or tetrabutyl ammonium iodide in a solvent which includes tetrahydrofuran (THF), acetonitrile, N,N ⁇ dimethylformamide (DMF) or N-methylpyrrolidinone, preferably THF to afford nitrile 6 followed by reduction with a reducing agent which includes tin chloride/HCI, lithium aluminum hydride and diisobutylaluminum hydride (DIBAL-H) preferably diisobutylaluminum hydride (DIBAL-H) followed by acid hydrolysis to give aldehyde 7.
- a reducing agent which includes tin chloride/HCI, lithium aluminum hydride and diisobutylaluminum hydr
- Aldehyde 7 is converted to nitrile 8 by the Strecker reaction with an alkali metal cyanide preferably potassium cyanide (KCN) or sodium cyanide (NaCN) or optionally with (dialkyl)aluminum cyanide or (trialkyl)silyl cyanide and an alkylamine (R 5 NH 2 ), optionally as a salt which includes the hydrochloride or hydrobromide salt, in an aqueous alcohol which includes methanol, ethanol, propanol and 2-propanol, preferably aqueous methanol, in quantitative yield.
- an alkali metal cyanide preferably potassium cyanide (KCN) or sodium cyanide (NaCN) or optionally with (dialkyl)aluminum cyanide or (trialkyl)silyl cyanide and an alkylamine (R 5 NH 2 ), optionally as a salt which includes the hydrochloride or hydrobromide salt, in an aqueous alcohol which includes
- Nitrile 8 is hydrolyzed to amide 9 by treating with an alkali metal hydroxide selected from the group lithium hydroxide (LiOH), sodium hydroxide and potassium hydroxide preferably lithium hydroxide optionally in the presence of an oxidizing agent such as hydrogen peroxide (H 2 0 2 ). Protection of the amine group of amide 9 as well as activation of the amide for hydrolysis is accomplished by reaction with an organic carbonate of the formula 0[C0 2 R 4 ] 2 where ⁇ is hereinbefore defined and each R 4 is taken independently in a solvent such as acetonitrile to afford blocked amine 10. Protecting with the tert- butoxycarbonyl (Boc) group is preferred.
- an alkali metal hydroxide selected from the group lithium hydroxide (LiOH), sodium hydroxide and potassium hydroxide preferably lithium hydroxide optionally in the presence of an oxidizing agent such as hydrogen peroxide (H 2 0 2 ). Protection of the amine group of amide 9 as well as activ
- Racemic blocked amine 12 is reacted with a resolving base (NH 2 -resolving base) 13 which include but are not limited to (S)-(-)- -methylbenzylamine, (S)-(-)- ⁇ -methyl-4- nitro-benzylamine, (1 R,2S)-(-)-norephedrin, and (1 S,2R)-(+)-norephedrin in a solvent such as ether to obtain the resolved blocked amine salt 14.
- a resolving base NH 2 -resolving base 13 which include but are not limited to (S)-(-)- -methylbenzylamine, (S)-(-)- ⁇ -methyl-4- nitro-benzylamine, (1 R,2S)-(-)-norephedrin, and (1 S,2R)-(+)-norephedrin in a solvent such as ether to obtain the resolved blocked amine salt 14.
- resolving base (S)-(-)- ⁇ -methylbenzylamine (SAMBA) is reacted with N-(tert-butoxycarbonyl)- N, ⁇ , ⁇ -trimethyl-L-phenylalanine to afford the salt of N-(tert-butoxycarbonyl)-N, ⁇ , ⁇ - trimethyl-L-phenylalanine with (S)-(-)- -methylbenzylamine (SAMBA) 14a.
- Resolved blocked amine salt 14 is treated with an alkali metal hydroxide, further including sodium carbonate preferably aqueous sodium hydroxide or sodium carbonate and the product as Formula I is isolated after further reaction with acid to afford compounds of Formula I.
- Commonly used acids include hydrochloric and sulfuric, preferably citric acid.
- racemic blocked amine 12 is reacted with a resolving base (NH 2 -resolving base) 13 which includes (R)-(+)- ⁇ -methylbenzylamine to afford the (R) resolved blocked amine salt which may be treated with an alkali metal hydroxide using conditions as described in Scheme I to give the (R) free carboxylic acid.
- a resolving base (NH 2 -resolving base) 13 which includes (R)-(+)- ⁇ -methylbenzylamine
- the substituted oxirane 16 is selectively rearranged (>98% phenyl migration) to give aldehyde 7 upon treatment with a catalytic amount (5 mol%) of fr/s(pentafluorophenyl) borane [(C 6 F 5 ) 3 B] in benzene (Yamamoto, H. et al Synlett 1995, 721) followed by subsequent treatment with (S)-(+)-p-toluenesulf ⁇ namide 17 and titanium ethoxide [Ti(OEt) 4 ] to produce (S)-substituted-p-toluenesulfinamide 18 (Davis et al, J. Org. Chem. 1999, 64, 1403).
- aldehyde 7 is 2-methyl-2-phenylpropanal
- an 88:12 mixture of the diastereomeric (S s ,2S)-N-(p- toluenesulfinyl)-2-amino-3-methyl-3-phenylbutyronitrile and (S s ,2R)-N-(p- toluenesulfinyl)-2-amino-3-methyl-3-phenylbutyronitrile 19 (Davis, et al J. Org. Chem. 1996, 61, 440) is formed. Nitrogen alkylation (Semko, CM. et al J. Org. Chem.
- nitrile 19 is a mixture of (S s ,2S)-N-(p-toluenesulfinyl)-2-amino-3-methyl-3- phenylbutyronitrile and (S s ,2R)-N-(p-toluenesulfinyl)-2-amino-3-methyl-3- phenylbutyronitrile further reaction with an alkali metal hydroxide, preferably potassium hydroxide (KOH), tetrabutylammonium bromide(TBAB) and R 5 LG is preferably iodomethane (CH 3 I) in THF generated the corresponding (S s ,2S)-N-(p- toluenesulfinamido-methyl)-3-methyl-3-phenylbutanenitrile 20 with the absence of observable epimerization at C-2.
- an alkali metal hydroxide preferably potassium hydroxide (KOH), tetrabutylam
- the (S s ,2S)-N-(p-toluenesulfinamido-methyl)-3- methyl-3-phenylbutanenitrile 20 could be readily separated via flash chromatography or crystallization. Further, deblocking substituted amine 20 to remove the p- toluenesulfinyl group is achieved in methanolic HCI to give amine 21. Reaction of amine 21 with an alkali metal hydroxide preferably lithium hydroxide optionally in the presence of an oxidizing agent such as hydrogen peroxide affords amide 22.
- Protection of the amine group of amide 22 is accomplished by reaction with an organic carbonate of the formula 0[C0 2 R ] 2 where R 4 is hereinbefore defined in a solvent such as acetonitrile to afford blocked amine 23 optionally isolated.
- a solvent such as acetonitrile
- Block amine 23 optionally isolated.
- Protecting with the ferf-butoxycarbonyl (Boc) group is preferred.
- Further reaction of blocked amine 23 with an organic carbonate of the formula O[CO 2 R ] 2 preferably di-tert-butyl dicarbonate in the presence of dimethylaminopyridine(DMAP) (at about 10% mol.
- DMAP dimethylaminopyridine
- triblocked amide 24 Hydrolysis of triblocked amide 24 with an alkali metal hydroxide preferably sodium hydroxide followed by acidifying with common acids which include hydrochloric and sulfuric, preferably with citric acid, to a pH 6 or less, preferably to a pH of 3-6, more preferably 4-6 and most preferably to 5-6 with citric acid afford compounds of Formula I.
- an alkali metal hydroxide preferably sodium hydroxide
- common acids which include hydrochloric and sulfuric, preferably with citric acid, to a pH 6 or less, preferably to a pH of 3-6, more preferably 4-6 and most preferably to 5-6 with citric acid afford compounds of Formula I.
- carboxylic acid 25 is prepared by hydrolysis of nitrile 8 by refluxing in concentrated hydrochloric acid. Coupling of carboxylic acid 25 with amine 26 in the presence of a coupling agent and an organic base affords ester 28 followed by alkaline metal hydroxide hydrolysis, preferably lithium hydroxide to obtain carboxylic acid 29.
- Preferred coupling agents are selected from the group N,N'- dicyclohexylcarbodiimide plus 1-hydroxybenzotriazole, benzotriazol- - yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP-reagent), N,N'bis[2- oxo-3-oxazolidinyl]phosphorodiamidic chloride (BOB Cl), diphenylphosphinyl chloride (DPP-CI), diethoxyphosphoryl cyanide, 2-chloro-1-methylpyridinium iodide, phenyldichlorophosphate plus imidazole, 2-(1H-benzotriazole-1-yl)-1, 1,3,3- tetramethyluronium tetrafluoroborate, 2-(1 H-benzothazole-1 -yl)-1 ,1 ,3,3- tetramethyluronium hexafluorophosphate, bromo-
- a most preferred coupling agent is benzotriazole-1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate 27 and organic base N,N-diisopropylethylamine in methylene chloride.
- Preferred organic bases include: N,N-diisopropylethylamine, N- methylmorpholine, N-methylpyrrolidine, triethylamine, 4-dimethylaminopyridine, 2,6-di- tert-butyl-4-methylpyridine and pyridine.
- the reaction mixture is stirred for 17 hours and the organic phase is separated.
- the aqueous layer is extracted with ethyl acetate (400 mL) and the combined organic layers are washed with water (300 mL), brine (300 mL) and dried over Na 2 S0 4 .
- the organic extracts are filtered and concentrated to give 2-methyl -2-phenylpropanal as an oil (275 g, 92.8% yield, 98.2% by HPLC area).
- N, ⁇ , ⁇ -trimethylphenylalaninamide 2.0 g, 9.7 mmol
- acetonitrile 6.0 mL
- di-ferf-butyl dicarbonate 2.33 g, 10.6 mmol
- acetonitrile 6.0 mL
- the reaction mixture is filtered and the product washed with acetonitrile (3 mL x 2) to afford N-(tert-butoxycarbonyl)-N, ⁇ , ⁇ - trimethylphenylalaninamide (1.12 g, 40%, 97.6% HPLC area) as a white solid.
- N, ⁇ , ⁇ -trimethylphenylalaninamide (83.0 g, 0.402 mol, 80% by HPLC area) in acetonitrile (500 mL) is added Boc 2 O (316 g, 1.45 mol).
- Boc 2 O (316 g, 1.45 mol).
- N,N-dimethylaminopyridine (4.90g, 0.0401 mol) and diisopropylethylamine (77.0 mL, 0.442 mol) are then added. After the mixture is stirred for 24 hours, water (1000 mL) is added.
- N,N,N- tris(tert-butoxycarbonyl)-N, ⁇ , ⁇ -trimethylphenylalaninamide ( 202 g).
- N,N,N-tris(tert-butoxycarbonyl)-N, ⁇ , ⁇ -trimethylphenylalaninamide is dissolved in tetrahydrofuran (402 mL) and aqueous NaOH (5N, 402 mL) is added with vigorous stirring. After stirring for 4 hours, water (400 mL) is added.
- the solid is filtered off and washed with NaOH (0.5N, 3x200 mL).
- the mother liquor is concentrated under vacuum to remove the tetrahydrofuran.
- the mixture is extracted with ethyl acetate (3x500mL).
- the combined organic extracts are washed with brine and dried over Na 2 S0 4 .
- the organic extracts are filtered and concentrated to give N-(tert- butoxycarbonyl)-N, ⁇ , ⁇ -trimethylphenylalanine as an oil (81.0 g, 82% yield, 99.9% by HPLC area).
- the reaction mixture containing the 2-methyl -2-phenylpropanal is then treated with (S)-p-toluenesulfinamide (2.3 g, 15 mmol) followed by a solution of 16 mL (73 mmol) titanium ethoxide in 155 mL of benzene.
- the yellow solution is stirred at 25°C for 24 hours then cooled to 5 - 10 °C and quenched with 245 mL of water.
- the mixture is filtered through diatomaceous earth, and the filter cake washed with methylene chloride (4 x 50 mL).
- the aqueous layer is washed with methylene chloride (1 x 25 mL).
- the combined organic layers are dried (MgS0 4 ) and concentrated under reduced pressure to give 3.74 g (81%) of the desired product as a white solid.
- the product is used without further purification in the next step.
- the reaction mixture is kept at -78 °C for 20 minutes., then warmed to 25°C and stirred for 1 hour.
- the reaction mixture is recooled to -78 °C and quenched with saturated ammonium chloride (86 mL).
- the resulting mixture is diluted with ethyl acetate (120 mL) and filtered through diatomaceous earth.
- the filter cake is washed with ethyl acetate (40 mL), and the organic layer is dried (MgS0 4 ) and concentrated under reduced pressure to give the desired product as a tan oil (3.9 g, 105%) which is used without further purification in the next step.
- the reaction mixture is kept at 0-5 °C for 50 minutes, then transferred to a separatory funnel containing diethyl ether (80 mL) and water (8 mL).
- the organic layer is washed with water (2 x 8 mL) and brine (1 x 4 mL), dried (MgS0 ), and concentrated under reduced pressure to give 0.45 g of a yellow oil.
- the crude product is purified by flash chromatography (FlashEluteTM 40M cartridge, 78:22 hexane:ethyl acetate, 60 x 8 mL fractions) to give 91 mg (18%) of the desired product as a white solid (>95% de by 1 H NMR). Recrystallization from methylene chloride/hexanes afforded the desired product as long transparent rods which are judged to be >99% pure diastereomer by 1 H NMR.
- the stereochemical assignments are verified by x-ray crystallography.
- the salt is suspended in ether (30 mL) and 0.4 mL (2.9 mmol) of triethylamine is added. The mixture is stirred for 20 minutes and filtered. The filtrate is concentrated under reduced pressure to give 0.48 g (90%) of the desired product as a colorless oil.
- reaction mixture is filtered, washed with heptane (3 x 3mL), and acidified with citric acid.
- N-(tert-butoxycarbonyl)-N, ⁇ , ⁇ - trimethyl-L-phenylalanine (0.33 g, 41%) is obtained by extraction with ethyl acetate followed by concentration.
- N, ⁇ , ⁇ -trimethylphenylalanine (0.511 g, 2.47 mmol) is suspended in methylene chloride (7 mL) followed by addition of N,N-diisopropylethylamine (0.87 mL; 5.00 mmol) and a solution of ethyl (2E,4S)-2,5-dimethyl-4-[methyl(3-methyl-L-valyl)amino]hex-2-enoate (2.63 mmol) in methylene chloride (3 mL).
- the mixture is cooled to 3.5 °C and the coupling reagent (benzotriazole-1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate; 1.24 g; 2.39 mmol) is added portionwise.
- the reaction mixture is stirred overnight under nitrogen.
- Example 15 N, ⁇ , ⁇ -trimethylphenylalanyl-N 1 -[(1S,2E)-3-carboethoxy-1-isopropylbut-2-enyl]-N 1 ,3- dimethyl-L-valinamide (Example 15) is hydrolyzed in the presence of base to obtain the product of the example.
- Example 17 N, ⁇ , ⁇ -Trimethyl-L-phenylalanyl-N 1 -[(1 S,2E)-3-carboethoxy-1 -isopropyl-but-2-enyl-N 1 ,3- dimethyl-L-valinamide
- Example 15 Using the conditions of Example 15 and N, ⁇ , ⁇ -trimethyl-L-phenylalanine the product of the Example may be obtained.
- Example 16 Using the conditions of Example 16, and the product of Example 17, the product of the Example may be obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0314128-4A BR0314128A (en) | 2002-09-20 | 2003-09-12 | Process for the preparation of useful intermediates for the synthesis of tubulin inhibitors |
AU2003299042A AU2003299042A1 (en) | 2002-09-20 | 2003-09-12 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
CA002498759A CA2498759A1 (en) | 2002-09-20 | 2003-09-12 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
MXPA05002874A MXPA05002874A (en) | 2002-09-20 | 2003-09-12 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors. |
EP03797903A EP1539682A2 (en) | 2002-09-20 | 2003-09-12 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
JP2004537780A JP2006500407A (en) | 2002-09-20 | 2003-09-12 | Methods for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
NO20051146A NO20051146L (en) | 2002-09-20 | 2005-03-03 | Process for the preparation of intermediates useful for the preparation of tubulin inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41202402P | 2002-09-20 | 2002-09-20 | |
US60/412,024 | 2002-09-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004026814A2 true WO2004026814A2 (en) | 2004-04-01 |
WO2004026814A3 WO2004026814A3 (en) | 2004-08-12 |
Family
ID=32030783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/028661 WO2004026814A2 (en) | 2002-09-20 | 2003-09-12 | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors |
Country Status (16)
Country | Link |
---|---|
US (2) | US6951955B2 (en) |
EP (1) | EP1539682A2 (en) |
JP (1) | JP2006500407A (en) |
KR (1) | KR20050054951A (en) |
CN (1) | CN1705639A (en) |
AR (1) | AR041321A1 (en) |
AU (1) | AU2003299042A1 (en) |
BR (1) | BR0314128A (en) |
CA (1) | CA2498759A1 (en) |
EC (1) | ECSP055693A (en) |
MX (1) | MXPA05002874A (en) |
NO (1) | NO20051146L (en) |
RU (1) | RU2005111753A (en) |
TW (1) | TW200409745A (en) |
WO (1) | WO2004026814A2 (en) |
ZA (1) | ZA200502275B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009500368A (en) * | 2005-06-30 | 2009-01-08 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Synthesis of deoxybiotinyl hexamethylenediamine-DOTA |
CN102485726A (en) * | 2010-12-02 | 2012-06-06 | 上海药明康德新药开发有限公司 | Method for preparing 1-R-1'-spiro-(piperidine-4,4'-quinoline)-2'(3'-hydrogen)ketone |
US9522876B2 (en) | 2013-03-15 | 2016-12-20 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US9879086B2 (en) | 2014-09-17 | 2018-01-30 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
US11560422B2 (en) | 2013-12-27 | 2023-01-24 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5091406B2 (en) * | 2002-11-21 | 2012-12-05 | ハドコ サンタ クララ,インコーポレイテッド | Laser trimming of resistors |
US7297896B2 (en) * | 2002-11-21 | 2007-11-20 | Hadco Santa Clara, Inc. | Laser trimming of resistors |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
TWI758313B (en) * | 2016-10-12 | 2022-03-21 | 美商陶氏農業科學公司 | Process for the preparation of (1r,3r)- and (1s,3s)-2,2-dihalo-3-(substituted phenyl)cyclopropanecarboxylic acids |
CN109580801B (en) * | 2018-06-26 | 2021-09-07 | 深圳海王医药科技研究院有限公司 | High performance liquid chromatography for detecting tubulin inhibitor and related impurities |
CN110343056B (en) * | 2019-07-19 | 2022-01-07 | 爱斯特(成都)生物制药股份有限公司 | Preparation method of N-tert-butyloxycarbonyl-N-methyl-2-amino-4, 4-dimethylpentanoic acid |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033211A1 (en) * | 1995-04-20 | 1996-10-24 | University Of British Columbia | Biologically active peptides and compositions, their use |
WO1999032509A2 (en) * | 1997-12-19 | 1999-07-01 | The University Of British Columbia | Hemiasterlin analogs |
WO2003072754A2 (en) * | 2002-02-27 | 2003-09-04 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2884081B1 (en) * | 1998-02-13 | 1999-04-19 | 名古屋大学長 | Method for producing aldehydes or ketones using aryl boron compound catalyst |
-
2003
- 2003-09-12 CA CA002498759A patent/CA2498759A1/en not_active Abandoned
- 2003-09-12 KR KR1020057004742A patent/KR20050054951A/en not_active Application Discontinuation
- 2003-09-12 AU AU2003299042A patent/AU2003299042A1/en not_active Abandoned
- 2003-09-12 BR BR0314128-4A patent/BR0314128A/en not_active Application Discontinuation
- 2003-09-12 CN CNA038251892A patent/CN1705639A/en active Pending
- 2003-09-12 MX MXPA05002874A patent/MXPA05002874A/en unknown
- 2003-09-12 JP JP2004537780A patent/JP2006500407A/en active Pending
- 2003-09-12 RU RU2005111753/04A patent/RU2005111753A/en not_active Application Discontinuation
- 2003-09-12 EP EP03797903A patent/EP1539682A2/en not_active Withdrawn
- 2003-09-12 WO PCT/US2003/028661 patent/WO2004026814A2/en not_active Application Discontinuation
- 2003-09-18 TW TW092125722A patent/TW200409745A/en unknown
- 2003-09-18 US US10/664,724 patent/US6951955B2/en not_active Expired - Fee Related
- 2003-09-19 AR ARP030103411A patent/AR041321A1/en unknown
-
2005
- 2005-03-03 NO NO20051146A patent/NO20051146L/en unknown
- 2005-03-17 ZA ZA200502275A patent/ZA200502275B/en unknown
- 2005-03-21 EC EC2005005693A patent/ECSP055693A/en unknown
- 2005-08-11 US US11/202,116 patent/US7078572B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033211A1 (en) * | 1995-04-20 | 1996-10-24 | University Of British Columbia | Biologically active peptides and compositions, their use |
WO1999032509A2 (en) * | 1997-12-19 | 1999-07-01 | The University Of British Columbia | Hemiasterlin analogs |
WO2003072754A2 (en) * | 2002-02-27 | 2003-09-04 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
Non-Patent Citations (13)
Title |
---|
ANDERSEN R J ET AL: "Total synthesis of (Ð?)-hemiasterlin, a structurally novel tripeptide that exhibits potent cytotoxic activity" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 38, no. 3, 20 January 1997 (1997-01-20), pages 317-320, XP004014996 ISSN: 0040-4039 * |
CÉCILE PASCAL ET AL.: "Synthesis of Biphenyls mimicking the struture of the antimitotic rhazinilam" JOURNAL OF ORGANIC CHEMISTRY., vol. 63, no. 18, 1998, pages 6414-6420, XP002281133 EASTON US * |
CHANDRASEKHAR S ET AL: "Highly efficient cleavage of epoxides catalyzed by B(C6F5)3" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 43, no. 21, 20 May 2002 (2002-05-20), pages 3801-3803, XP004352410 ISSN: 0040-4039 * |
CHEMICAL ABSTRACTS, vol. 123, no. 25, 18 December 1995 (1995-12-18) Columbus, Ohio, US; abstract no. 338597b, ISHIHARA, KAZUAKI ET AL.: "Tris(pentafluorophenyl)boron as an efficient catalyst in the stereoselective rearrangment of epoxides." page 1042; column 1; XP002281134 & SYNLETT, vol. 7, 1995, pages 721-722, * |
DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; Database-Accession no. 277319 (reaction ID), XP002273035 & ANN. CHIM. (PARIS), vol. 8, no. 10, 1907, page 364 * |
DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; Database-Accession no. 5474988 (ID), XP002281136 & BULL. SOC. CHIM., vol. 4, no. 49, 1931, pages 1782-1786, * |
DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; Database-Accession no. 5556421 (ID), XP002281135 & BULL. SOC CHIM., vol. 4, no. 33, 1923, page 757 * |
EDWIN VEDEJS ET AL.: "A total synthesis of (-)-Hemiasterlin using N-Bts methodology" JOURNAL OF ORGANIC CHEMISTRY., vol. 66, no. 22, 2001, pages 7355-7364, XP002273033 EASTON US cited in the application * |
J.P. BROWN ET AL.: "The chemistry of fungi." JOURNAL OF THE CHEMICAL SOCIETY., 1949, pages 859-867, XP001189487 LETCHWORTH GB * |
N. M. WALDRON ET AL.: "The constitution of the dimers ....." JOURNAL OF THE CHEMICAL SOCIETY., 1968, pages 1914-1917, XP001189486 LETCHWORTH GB * |
NIEMAN J A ET AL: "Synthesis and Antimitotic/Cytotoxic Activity of Hemiasterlin Analogues" JOURNAL OF NATURAL PRODUCTS, vol. 66, no. 2, 2003, pages 183-199, XP002249342 ISSN: 0163-3864 * |
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 13, 30 November 1999 (1999-11-30) & JP 11 228479 A (UNIV NAGOYA), 24 August 1999 (1999-08-24) * |
T. K. CHAKRABORTY ET AL.: "Diastereoselective strecker synthesis using alpha-phenylglycinol as chiral auxiliary" TETRAHEDRON LETTERS., vol. 32, no. 51, 1991, pages 7597-7600, XP002273034 OXFORD GB cited in the application * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009500368A (en) * | 2005-06-30 | 2009-01-08 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Synthesis of deoxybiotinyl hexamethylenediamine-DOTA |
CN102485726A (en) * | 2010-12-02 | 2012-06-06 | 上海药明康德新药开发有限公司 | Method for preparing 1-R-1'-spiro-(piperidine-4,4'-quinoline)-2'(3'-hydrogen)ketone |
CN102485726B (en) * | 2010-12-02 | 2015-07-01 | 天津药明康德新药开发有限公司 | Method for preparing 1-R-1'-spiro-(piperidine-4,4'-quinoline)-2'(3'-hydrogen) ketone |
US9522876B2 (en) | 2013-03-15 | 2016-12-20 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10201614B2 (en) | 2013-03-15 | 2019-02-12 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US11617777B2 (en) | 2013-03-15 | 2023-04-04 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
US11560422B2 (en) | 2013-12-27 | 2023-01-24 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
US9879086B2 (en) | 2014-09-17 | 2018-01-30 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10414822B2 (en) | 2014-09-17 | 2019-09-17 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US10450378B2 (en) | 2014-09-17 | 2019-10-22 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
US11591405B2 (en) | 2014-09-17 | 2023-02-28 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
NO20051146L (en) | 2005-04-18 |
AR041321A1 (en) | 2005-05-11 |
RU2005111753A (en) | 2005-11-20 |
MXPA05002874A (en) | 2005-05-27 |
US7078572B2 (en) | 2006-07-18 |
AU2003299042A1 (en) | 2004-04-08 |
BR0314128A (en) | 2005-06-28 |
US20050288486A1 (en) | 2005-12-29 |
US20040063904A1 (en) | 2004-04-01 |
WO2004026814A3 (en) | 2004-08-12 |
ZA200502275B (en) | 2007-10-31 |
ECSP055693A (en) | 2005-05-30 |
US6951955B2 (en) | 2005-10-04 |
JP2006500407A (en) | 2006-01-05 |
EP1539682A2 (en) | 2005-06-15 |
CN1705639A (en) | 2005-12-07 |
TW200409745A (en) | 2004-06-16 |
CA2498759A1 (en) | 2004-04-01 |
KR20050054951A (en) | 2005-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7078572B2 (en) | Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors | |
KR20190057437A (en) | Lysin-glutamic acid dipeptide derivatives | |
KR20080014011A (en) | Process for preparing renin inhibitors | |
KR20120128667A (en) | A process for the preparation of lacosamide | |
JP2611816B2 (en) | Method for O-alkylation of N- (hydroxy) aralkylphenylethanolamines | |
ES2528701T3 (en) | Aliskiren Synthesis | |
JPWO2016002918A1 (en) | Method for producing indole compound | |
EP0635493A2 (en) | Process for the preparationof a beta-aminoalcohol | |
AU2017336606A1 (en) | An improved process for the preparation of lacosamide | |
JP3054163B2 (en) | Phosphinic acid ester-containing N-acyl-2-amino acid amide, process for producing the same and N-acyl-2-amino acid nitrile as precursor | |
KR100915551B1 (en) | Process for the efficient preparation of 3-hydroxy pyrrolidine and derivatives thereof | |
EP1926709A1 (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
WO2020110146A1 (en) | Process for the preparation of high pure eribulin and its mesylate salt | |
KR20070024390A (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
JP5704763B2 (en) | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivative | |
JP2010031004A (en) | New imidazole derivative, method for producing the same, and method for producing histidine amide derivative using the imidazole derivative | |
EP2050738B1 (en) | Novel imidazolidinone derivative, method of producing the same and method of producing optically active amino acid | |
JP2004238322A (en) | Method for producing (r)-3-aminopentanenitrile methanesulfonic acid salt | |
KR101859586B1 (en) | Process for the preparation of lacosamide or its analogues | |
FR2692909A1 (en) | Process for the preparation of optically pure substituted aryl-1 alkanols | |
JP4157175B2 (en) | Method for producing 2'-pyrrolidinepropanoic acid derivative | |
KR0145799B1 (en) | A process for preparing an optically pure monovalent amine | |
KR101492351B1 (en) | Method for producing amino acid amide derivative having fluorine-containing carbamate group, production intermediate thereof, and method for producing ethylene diamine derivative | |
Lohray et al. | Nucleophilic reaction of glycidol tosylate and the corresponding cyclic sulphate with various nucleophiles: A comparative study ǂ | |
JPH1045721A (en) | Production of 1-substituted-4,5-diphenyl-2-imidazolidinone and intermediate for the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003797903 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003299042 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2498759 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 167419 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/002874 Country of ref document: MX Ref document number: 428/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 538854 Country of ref document: NZ Ref document number: 05024708 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500550 Country of ref document: PH Ref document number: 200502275 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057004742 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004537780 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2005111753 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500506 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038251892 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057004742 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003797903 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003797903 Country of ref document: EP |